We can deliver the entire programme of drug discovery (from chemistry through to in vivo and in vitro studies in state of the art preclinical models of disease to secure an investigational new drug (IND) approval to begin clinical trials.
Our philosophy is to eliminate compromises: to deliver more high quality data, quickly and at lower cost. Uniquely, RxCelerate provides tailored combination study designs, giving you more insight per pound than conventional approaches. Our team also offers a comprehensive range of ex vivo analysis services to maximise information collected from in vivo studies.
Sometimes you need to go beyond the requirements of the regulatory regime to examine specific side-effects already known, or suspected, to be associated with a particular mechanism of action. General toxicology, incorporating histopathology and clinical chemistry, will identify significant, unexpected toxicities.
Contact RxCelerate to design a faster, better preclinical development programme for your drug candidate.